757 completed, 351 unknown, 291 recruiting, 196 terminated. 1262 Phase 2, 391 Phase 1, 383 Phase 3, 47 Not applicable, 25 Phase 4.
Follow Oxaliplatin: new trials by email Literature Review of Oxaliplatin trials Research Report on Oxaliplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2027-04-01 | 2026-11-04 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 42 | 2026-12-15 | 2026-10-29 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 33 | 2026-12-01 | 2026-11-12 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Oxaliplatin, 5-Fluorouracil, Capecitabine - Biliary Tract Cancer, Cholangiocarcinoma | Phase 3 | Not yet recruiting | Zhai Wenlong | 90 | 2026-11-30 | 2026-11-04 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 500 | 2026-11-25 | 2026-11-04 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer | Phase 3 | Not yet recruiting | Fudan University | 394 | 2026-11-15 | 2026-11-12 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin] - Pancreatic Cancer, Borderline Resectable Pancreatic Cancer | Not applicable | Recruiting | IMGT Co., Ltd. | 366 | 2026-11-04 | 2026-11-09 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin - Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 34 | 2026-11-01 | 2026-09-18 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma Glofitamab, Gemcitabine, Oxaliplatin - PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 40 | 2026-11-01 | 2026-10-22 |
| Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer DCSZ11, Radiation, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2026-11-01 | 2026-10-28 |
| RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma RC118(Dose 1) plus RC148(Dose 1), RC118(Dose 1) plus RC148(Dose 2), RC118(Dose 2) plus RC148(Dose 1) - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | 680 | 2026-11-01 | 2026-11-13 |
Showing 20 of 1909. Sign in to see all of them.
Colorectal Neoplasms (457) · Stomach Neoplasms (307) · Rectal Neoplasms (272) · Colonic Neoplasms (192) · Pancreatic Neoplasms (176) · Neoplasm Metastasis (112) · Esophageal Neoplasms (88) · Neoplasms (71) · Carcinoma, Hepatocellular (61) · Adenocarcinoma Of Esophagus (55) · Adenocarcinoma (50) · Lymphoma, Large B-Cell, Diffuse (48) · Cholangiocarcinoma (46) · Carcinoma, Non-Small-Cell Lung (41) · Biliary Tract Neoplasms (40)
National Cancer Institute (NCI) (65) · Sun Yat-sen University (57) · Fudan University (56) · Hoffmann-La Roche (44) · Sanofi (39) · M.D. Anderson Cancer Center (32) · Alliance for Clinical Trials in Oncology (27) · UNICANCER (24) · The First Affiliated Hospital with Nanjing Medical University (21) · Merck Sharp & Dohme LLC (20) · Fujian Cancer Hospital (19) · Memorial Sloan Kettering Cancer Center (19) · Eli Lilly and Company (18) · GERCOR - Multidisciplinary Oncology Cooperative Group (18) · Gruppo Oncologico del Nord-Ovest (14)
United States (688) · China (583) · France (180) · South Korea (152) · Germany (132) · Italy (124) · Spain (123) · Canada (107) · United Kingdom (104) · Japan (100) · Taiwan (83) · Belgium (77) · Australia (75) · Poland (52) · Brazil (50)
Project Leader (9) · Norman Wolmark, MD (8) · Alfredo Falcone, MD (5) · Dae Young Zang, MD, PhD (5) · Howard S. Hochster, MD (5) · Jane Robertson (5) · Jiren Yu (5)
PMID 36306483, PMID 35623069, PMID 32816630, PMID 33356421, PMID 40341124, PMID 40812353, PMID 31268130, PMID 40340830, PMID 22226517, PMID 30679026, PMID 31378656, PMID 32085892, PMID 33439695, PMID 33538338, PMID 12049862, PMID 12540794, PMID 15908661, PMID 21444866, PMID 21561347, PMID 21831266, PMID 21997132, PMID 24901360, PMID 24982456, PMID 26187751, PMID 26861604, PMID 27275632, PMID 27986363, PMID 28006055, PMID 28237539, PMID 29471013, PMID 30566590, PMID 30982686, PMID 31070690, PMID 31557064, PMID 31765987, PMID 31811950, PMID 32418078, PMID 32939319, PMID 34905388, PMID 35594613, PMID 36525610, PMID 36940261, PMID 37678921, PMID 37963317, PMID 38315963, PMID 38347302, PMID 38564700, PMID 38861294, PMID 40373876, PMID 40680855
2023 (18), 2016 (17), 2018 (15), 2025 (13), 2015 (10), 2017 (10), P30CA033572 (8), U10CA021115 (8), U10CA032102 (8), P30CA043703 (7), U10CA180820 (7), U10CA180821 (7), 2009 (6), 2014 (6), U10CA180868 (6)